Navigation Links
Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors
Date:4/22/2009

BELGIUM, Wis., April 22 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), an innovative, global wellness solutions company, announces that its BioPharm Process Systems operating group (BPS), operating under the MPS-BioPharm name (MPS), received both a contract and deposit from American Beef Processors (ABP) to utilize MPS' Equity by Design(TM) product.

MPS will evaluate all equipment designs for fit and purpose related to design, constructability and cleanliness. MPS will also provide a final report, identifying budget cost to complete project, facility and facility needs to support the process, as well as identifying gaps to be resolved within the proposed process and any associated risks with the proposed process.

Rick Kramer, Managing Director of Mach One's BioPharm Process Systems Group said, "Equity by Design(TM) is a program whereby MPS provides certain Technical Advisory Services in which it takes part of its compensation in the form of Equity related securities. In circumstances where the client has a business model that compliments the 'wellness vision' and where the business model has a implied enterprise valuation of at least $500 million, MPS will negotiate its compensation such that it participates in the upside valuation to which its Technical Advisory Services contribute."

About Mach One Corporation:

Mach One Corporation (www.machonecorp.com) is a global wellness company that provides biotechnology based solutions to help address one of the world's most pressing and costly needs -- positive, long-term health and longevity benefits for humans and disease-threatened animals of commercial operations. While animal wellness, organic and sustainable products are our initial primary focus, we intend in the near future to add Nutraceuticals to our growing list of operating groups. As an ongoing objective we intend to be agile and swift in spotting business opportunities and respective businesses to expand our vision for positive contribution to global wellness.

About MPS-BioPharm:

BioPharm Process Systems (BPS) provides documentation, process modules, process skids, custom tanks and vessels and custom stainless steel fabrication to the biopharmaceutical, food and life sciences industries, with access to over 90,000 square feet of engineering and fabrication space as well as a highly trained, skilled workforce. Additional products and services include professional project management, DQ design qualifications, detailed design, component procurement, schedule metrics and reporting, data entry and ETOP (Enhanced Turn Over Package) modeling.

About American Beef Processing:

American Beef Processing, LLC (ABP), in conjunction with its licensor and other members of a consortium of partner organizations and Universities, has over the last several years, developed and built a commercial scale, boneless beef processing plant in Clackamus, Oregon. Using a unique design, the plant is designed to exploit the licenses granted and technologies developed during this period. The automated process is unique and entirely different to all other boneless beef processing systems. The ABP facility includes a "Bio-refinery" capable of separating a stream of tallow from boneless beef of any lean content grade such as 50's (50% lean), 65's 73's, 75's, 85's and even 90's- which comprises the majority of the 10 billion pound annual harvest of boneless beef by the US beef industry for sale to US consumers. The extracted "fat stream" is extracted as a food grade item but can be used as a feedstock for production of bio-diesel.

ABP will soon be installing a pathogen deactivating process capable of reducing pathogen (E.coli O157:H7, Listeria Monocytogenes, Salmonella) populations to undetectable levels (pathogen population reductions of >6Log). This anti-microbial process is also unique, incorporating a process of rapid, alternating immersion of the entire input stream of boneless beef/trim in sub critical and super critical carbon dioxide under controlled pressure (and temperature) and exposure time.

Additionally, ABP plans to install a market tested, anoxic, controlled atmosphere packaging system by the end of the first quarter 2010. This retail packaging process enables full semi-trailer loading (>40,000lbs compared to other, bulky, high oxygen MA systems which typically restrict semi-trailer loading to about 26,000lbs). This, extended shelf-life packaging process can reduce packaging material consumption by >50%.

Mach One strongly encourages the public to read the above information in conjunction with its Form 10-K for December 31, 2008. Mach One's disclosures can be viewed at www.machonecorp.com and www.sec.gov.

Cautionary Statement: This news release may include certain "Forward-looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.


'/>"/>
SOURCE Mach One Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
9. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
10. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
11. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... in the World Technology Awards. uBiome is one of just six company finalists ... categories. , In addition to uBiome, companies nominated as finalists in this year’s ...
(Date:12/8/2016)... PRINCETON, N.J. , Dec. 8, 2016 /PRNewswire/ ... a late-stage biopharmaceutical company focused on developing and ... is an unmet medical need, announced today the ... trial with SGX942 (dusquetide), a first-in-class Innate Defense ... (OM) in head and neck cancer patients undergoing ...
(Date:12/8/2016)... , Dec. 8, 2016  HedgePath Pharmaceuticals, ... that discovers, develops and plans to commercialize innovative ... shares of common stock were approved for trading ... begin trading on the OTCQX, effective today, under ... for the OTCQX market, companies must meet high ...
(Date:12/8/2016)... South Korea , Dec. 8, 2016 ... a $21 billion KRW (US $18.9M) Series A financing. ... Kolon Investment, G.N. Tech Venture and SNU Bio Angel. ... Eutilex to 30.5 billion KRW (US $27.7M) since its ... help Eutilex to bolster the development and commercialization of ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):